Summit Objectives:
Agenda details below In-person event- Miami, Florida To register, email curatingconnection@miami.edu for more information.
What is the Clinical Trials Summit? Rosenstiel School of Medicine Building (RMSB) 5th Floor What are the parking arrangements and directions? 1611 NW 12 Avenue Parking will be approximately $8-12 for the day Metro Rail Station: Civic Center stop Kindly consider South Florida traffic and allow yourself some extra travel time, wherever possible. Transportation & Parking Miller School of Medicine Miller School of Medicine Map and Directions | University of Miami How do I register? What is the closest airport? Miami International Airport (miami-airport.com) What are the lodging/accommodation options for out of town attendees? What meals are included with Clinical Trials Summit event registration? How do I let you know about my special dietary restrictions? Can I register at the venue? Will there be networking opportunities at the Clinical Trials Summit? How are the event sessions formatted? If I have questions, who can I contact? Credits The Compliance Certification Board (CCB)® has approved this event for up to 6.0 Live CCB CEUs, based on a 50-minute hour, each. Continuing Education Units are awarded based on individual attendance records. Granting of prior approval in no way constitutes endorsement by CCB of this event content or of the event sponsor. Who can I contact if I have additional questions? Please reach out to CuratingConnection@miami.edu for additional assistance.
A (1) day educational & networking interactive event focusing on clinical trials.
For more information:Curating Connection | Human Subject Research Office | University of Miami
When is the Clinical Trials Summit?
Wednesday, April 9th, 2025
Where will it take place?
The event will take place at the University of Miami Miller School of Medicine
1600 NW 10 Avenue, Miami, Fl. 33136
Security access, check in process- Event ID badges will be furnished upon arrival with prior registration
Closest Parking Garage:
Park Plaza West Garage, G-101
Miami, FL 33136 (Exit through North side and event venue is directly adjacent)
Advance registration is required through curatingconnection@miami.edu
Why attend the Clinical Trials Summit in Miami, Florida?
Miami is a thriving and vibrant South Florida community that boasts amazing weather and historic architecture, landmarks and residences. It offers much in the way of leisure to include renowned restaurants, delightful cafes, sprawling gardens, museums and with both high end and quaint little shops.
Florida Vacations, Travel & Tourism Guide | VISIT FLORIDA
Nearby shops:
Shopping & Services Miller School of Medicine
Miami International Airport (MIA) is about 8 miles from venue.
https://travel.miami.edu/travel-discounts/hotels/index.html
What is the event dress code?
Business professional attire; Comfortable shoes and sweater/ jacket recommended (in case room is chilly).
What is the expected weather for the Clinical Trials Summit?
High 70s/ Low 80s; Sunny
Light Breakfast, Coffee & Tea Service & Lunch; please check the agenda for times/ availability.
curatingconnection@miami.edu
In an effort to appropriately plan, we require prior event registration.
Yes! We have been very intentional about ‘curating connections’ where possible. You will have the opportunity to connect with local community partners, representatives from the FDA, investigators, study team members, various stakeholders from our Human Research Protection Program, including University leaders and IRB members.
Formats vary. Please visit the home page to view the agenda.
curatingconnection@miami.edu
The Society of Clinical Research Associates (SOCRA - www.SOCRA.org) accepts documentation of candidate participation in continuing education programs for recertification if the program is applicable to clinical research regulations, operations or management, or to the candidate’s clinical research therapeutic area. This program offers (6) hours of CE credit.
Emily Baldwin Emily Baldwin is a Bioresearch Monitoring Specialist as a Certified Investigator for the Office of Bioresearch Monitoring Inspectorate (OBMI) within the Office of Inspections and Investigations (OII) in the Food and Drug Administration (FDA). Throughout her FDA career, she has conducted domestic and international inspections to ensure human subject protection, and that data are reliable. Shari Targum, MD, MPH Shari Targum has over 35 years of combined regulatory, industry, policy and clinical experience. She earned her medical degree from the NYU Grossman School of Medicine and Masters in Public Health, with a Certificate in Health Policy and Management, from the Johns Hopkins Bloomberg School of Public Health. Shiowjen Lee, PhD Shiowjen Lee, PhD, is currently Deputy Director of the Division of Biostatistics, Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research (CBER), FDA. She joined CBER as a statistical reviewer in 2008 and became Team Lead of the Cell, Tissue and Gene Therapy team in 2012. Within these various roles, Dr. Lee led and closely involved in the approval of several innovative and high-profile gene/cellular therapy products. She has been active in working groups of several topics and guidance/policy development such as surrogate endpoint, biomarker, and real-world data/real-world evidence and, importantly, advising and helping with the professional development of Division staff. Prior to joining CBER, Dr. Lee worked as a statistical reviewer in Center for Drugs Evaluation and Research’s Office of Biostatistics and in Center for Devices and Radiological Health’s Division of Biostatistics. Dr. Lee has received numerous awards at the Center and FDA levels including the Outstanding Service award, the Team Excellence award, the Managerial Excellence award, and others. She holds a PhD in Statistics from the University of South Carolina. Sujatha Sridhar, MBBS, MCE Sujatha Sridhar, Associate Vice President for Research Compliance at the University of Texas Health Science Center at Houston, brings over 30 years of expertise in clinical research administration and human subjects protection. She oversees key compliance areas, including the Institutional Review Board, Institutional Animal Care and Use Committee, Stem Cell Research Oversight, and Conflict of Interest. Her responsibilities also encompass providing regulatory support for clinical trials, managing IND/IDEs, clinicaltrials.gov registration, coordinating research misconduct programs, and facilitating responsible conduct of research training. Sridhar is the co-lead of the CTSA workforce development core, a member of the Texas Medical Center Clinical Research Education committee and serves as a site visitor for the Association for Accreditation of Human Research Protection Programs. Shari Messinger, ME, PhD Shari Messinger, tenured Professor and Director of the Division of Biostatistics and Bioinformatics, Department Public Health Sciences of the Miller School of Medicine, and Director of the University of Miami Biostatistics Collaboration and Consulting Core (BCCC). DR. Messinger serves as Director of the Biostatistics, Epidemiology and Research Design Program of the Miami Clinical and Translational Sciences Institute (CTSI.) She has extensive knowledge and experience in application of appropriate statistical methodologies and is responsible for overseeing the biostatistics support for bench to bedside translation in her role as Director of the BCCC where she leads all collaboration and consulting activities provided by MS and PhD level BCCC staff statisticians. She teaches graduate courses and advises MS and Ph.D. students in Biostatistics. She has extensive knowledge and experience in the development, application, and education of appropriate statistical methodology for the analysis of clinical and translational investigations at every stage of research. Jennifer McCafferty-Fernandez, PhD Before launching Critical Path Advisors, Dr. McCafferty-Fernandez spent 10 years at Nicklaus Children’s Health System where she last served as the Senior Vice President and Chief of Staff at Nicklaus Children’s Health System, overseeing marketing and communications, government and community affairs, corporate governance and board support services as well as the patient and consumer experience activities for the System. Prior to Nicklaus, she was assistant provost and chief medical compliance & HIPAA privacy officer, among other roles, at the University of Miami and the Miller School of Medicine. She received Ph.D. in molecular and cellular pharmacology from the University of Miami, completed post-doctoral training at the Sylvester Comprehensive Cancer Center, and bachelor’s degree in chemistry from Maryville College. Proud mama of 4 amazing children and blessed to share her life with husband, Rudy Fernandez. In free time, Dr. McCafferty-Fernandez participates in community organizations like the South Florida YMCA, Live Like Bella Pediatric Cancer Foundation, and the United Way. Avid reader, love to bake and enjoys all the fantastic outdoor things that South Florida has to offer – especially college and professional sports (Go Canes, Heat, Dolphins, Marlins, Panthers, InterMiami, and her hometown Reds and Bengals)! Kenneth W. Goodman, PhD, FACMI, FACE Kenneth W. Goodman, Ph.D., FACMI, is founder and director of the University of Miami Miller School of Medicine’s Institute for Bioethics and Health Policy and its World Health Organization Collaborating Center in Ethics and Global Health Policy. He is a Professor of Medicine with appointments in the Department of Philosophy and others. He directs the Florida Bioethics Network and is responsible for ethics services for University of Miami Hospital, the UM Hospital and Clinics and the Jackson Health System. His research has emphasized issues in health information technology, including the use of computers in clinical care, research and public health. He has served on several institutional review boards, conflict-of-interest committees and research ethics review panels. Laura Kozma Laura Kozma, Associate Vice President for the Office of Research Administration, joined the University in September 2020. She provides leadership for sponsored administration which includes proposal review, processing, contract negotiations, award funding, expenditure, and compliance monitoring, and serves as audit liaison for the Institution for sponsored awards. In this same capacity, she is also responsible for sponsored cash management, university-wide reporting, and regulatory education and training programs. In addition, Ms. Kozma leads the facilities and administrative (indirect cost) rate calculation and negotiations and is responsible for the financial review and set-up of recharge centers. Previously Laura served as the Executive Director of Sponsored Program Services and Faculty Services at the University of Connecticut overseeing the office responsible for all sponsored awards under the Office of the Vice President for Research including the development of a new shared service department to improve and enhance administrative support for faculty related to sponsored awards. Prior to the University of Connecticut, Laura spent over ten years at Yale University in several roles including serving at the Assistant Director in the office of Grant and Contract Administration. Laura graduated cum laude from the University of Connecticut and obtained her Master of Arts degree from Southern Connecticut State University. Laura has been active in both NCURA and SRA, is a member of the Federal Demonstration Partnership (FDP) and serves as UM’s lead representative on the Council on Governmental Relations (COGR). Nicole S. McCullough, MS, CCRP Director, Regulatory Support Nicole McCullough is currently the Director of the Investigator Initiated Trial Services unit at the University of Miami Miller School of Medicine. The unit provides support to University of Miami investigator-initiated clinical trials conducted under an IND or IDE for FDA submissions, monitoring, safety management, data management and project management. Prior to re-joining the University of Miami in May 2022, Nicole worked at Nicklaus Children’s Health System where in her final three years she served as the Director of the Research Institute. Nicole has 24 years of research experience in the following areas: clinical research (protocol writing, operations/ coordination, regulatory, monitoring and compliance), laboratory research, and grants management (applications/pre-award and post-award financial management). Nicole earned a BS in Microbiology and a Master of Science in Molecular Biology from Louisiana State University. She has been a Certified Clinical Research Professional since 2005. Dr. Leigh Nattkemper, PhD Dr. Leigh Nattkemper is a Research Associate Professor and Director of Clinical Trials at the University of Miami Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery. She received her bachelor’s degree in microbiology and master’s degree in molecular medicine from the University of South Florida, then her Ph.D. in Neuroscience from Temple University. Her current research focus is to better understand the pathobiology of chronic pruritus, and to develop and test targeted treatments that will be effective for a wide array of diseases that suffer from chronic itch. Philip A. Arlen, PhD Dr. Arlen is Executive Director of Clinical Research Services at the University of Miami Sylvester Comprehensive Cancer Center, the only NCI-designated cancer center in South Florida. The Sylvester CRS supports interventional and non-interventional research studies, with a current portfolio of more than 300 open protocols and 3,000 research participants. Prior to joining the University of Miami, Dr. Arlen managed strategic alliances and partnerships on behalf of the Conrad Prebys Center for Chemical Genomics, the premier academic drug discovery program housed at Sanford Burnham Prebys Medical Discovery Institute. He then joined Diverse Biotech, Inc., an early-stage biotechnology company, where he headed R&D and led therapeutic development efforts. Dr. Arlen earned a BS in Biology from Cornell University and PhD in Microbiology, Immunology, and Molecular Genetics from the University of California, Los Angeles. His graduate research in HIV pathogenesis led to important discoveries in viral latency and therapeutic efficacy. After a post-doctoral fellowship in chloroplast transformation for the production of vaccines and pharmaceutical agents, he joined the MD Anderson Cancer Center as an assistant professor. There, he directed the Early-Stage Interventions Laboratory, which studied the relationship between cancer and the immune system, with specific areas of focus in cancer vaccines, tumor biomarkers, and immunodiagnostics. That research led to his first spin-out, Pandora Genomics, which developed novel strategies and tools for predicting treatment responses. Kenia Viamonte, MA Kenia Viamonte is the Director for the Human Subject Research Office (HSRO) and oversees the review of human subject research studies, the regulatory team that conducts HSR reviews, the five Institutional Review Boards (IRBs), and several compliance initiatives. She started at the University in 2002 at Medical Human Resources, where she was the recruiter for temporary staffing, and joined HSRO in 2005. She is well versed in the areas of IRB Operations, Research Compliance, Personnel Matters, Conflict Resolution, and Project Management. Kenia is the accreditation contact for the University through the Association for the Accreditation of Human Research Protection Programs (AAHRPP). She earned her Undergraduate and Graduate degrees from the University. Guillermo (Willy) Prado, PhD Guillermo (Willy) Prado is the University of Miami's chief academic officer, serving as interim provost and executive vice president for academic affairs. Prado is professor of Nursing and Health Studies, Public Health Sciences, and Psychology at the University of Miami. He is a pioneer in health disparities and behavioral interventions for the prevention of substance use, sexual risk behaviors, and depressive symptoms in Hispanic families. He has received approximately $30 million of continuous NIH and CDC funding since his doctoral studies as PI and over $100 million as Co-I, mentor, or collaborator. His research has led to over 200 peer-reviewed articles and chapters. For significantly advancing knowledge in the behavioral interventions, health disparities, and adolescent health literature, he has received numerous awards and honors, including the Lifetime Achievement Award from the National Hispanic Science Network; the Community, Culture, and Prevention Science Award from the Society for Prevention Research; and election to the prestigious National Academy of Medicine. His research has been featured in multiple media outlets including the Miami Herald, NBC, Univision, and CNN en Español. He has also been invited to serve as a witness to the U.S. House Select Committee on Economic Disparities and Fairness in Growth to speak about prevention science and health disparities. Stephen D. Nimer, MD Professor of Medicine, Biochemistry and Molecular Biology Stephen D. Nimer, M.D., is the director of the National Cancer Institute (NCI)-designated Sylvester Comprehensive Cancer Center. He is also the executive dean for research and a professor of medicine, biochemistry and molecular biology at the University of Miami Miller School of Medicine. Dr. Nimer's career spans more than 30 years in clinical care, research, administration and leadership. Maria Luisa Alcaide, MD Dr. Maria Alcaide is the Vice Provost for Research and Scholarship at the University of Miami. Dr. Alcaide is an Infectious Diseases physician scientist, Professor of Medicine, OB/GYN, and Public Health Sciences at the University of Miami Miller School of Medicine. Through these roles, she provides guidance and recommendations on the conduction and strategic plan for research at the Miller School of Medicine, and scientific and administrative oversight to multiple multidisciplinary research studies focused on HIV and other emerging infections. Dr. Alcaide received her medical degree at the Universidad Autonoma de Madrid and completed her residency in internal medicine and fellowship in Infectious Diseases at the University of Miami/Jackson Memorial Hospital in 2007. Dr. Alcaide has been continuously funded by NIH since 2009 and is among the top funded investigators at the University of Miami. She conducts large NIH funded multidisciplinary clinical and epidemiological studies in infectious diseases the US and international settings.
Certified Investigator, Specialist
Office of Bioresearch Monitoring Inspectorate (OBMI)
Office of Inspections and Investigations (OII)
Food and Drug Administration (FDA)
Deputy Director, Office of Clinical Policy, Office of the Chief Medical Officer in the Office of the Commissioner
US Food & Drug Administration
Dr. Targum joined FDA in 1999 as a medical officer and team leader in the Division of Cardiovascular and Renal Products, Office of New Drugs, CDER. She served in positions of increasing responsibility and is currently Deputy Director, Office of Clinical Policy, Office of the Chief Medical Officer in the Office of the Commissioner.
Dr. Targum has given over 35 invited talks and co-authored 17 publications related to FDA work. She has served on numerous working groups, participated in grant reviews and development of FDA guidances and has won 15 FDA awards. She is board-certified in internal medicine and cardiology; she maintains staff privileges and continues to follow patients at the Washington DC VA Medical Center.
Deputy Director, Division of Biostatistics Office of Biostatistics & Pharmacovigilance Center for Biologics Evaluation and Research
US Food & Drug Administration
Associate Vice President, Research Compliance
UT Health, Houston
Professor and Director Division of Biostatistics and Bioinformatics
Director, Collaboration and Consulting Core
Department of Public Health Sciences
University of Miami Miller School of Medicine
Managing Partner
Critical Path Advisors, LLC
Director, Institute for Bioethics and Health Policy
Director, University of Miami Ethics Programs
Associate Vice President
Office of Research Administration
University of Miami
Investigator Initiated Trial Services at the U (IITS-U)
Office of the Executive Dean for Research
University of Miami Miller School of Medicine
Associate Professor
Director of Clinical Trials
Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery
Miami Itch Center
University of Miami
Executive Director, Clinical Research Services Sylvester Comprehensive Cancer Center
University of Miami
Director, Human Subject Research
University of Miami
Executive Vice President for Academic Affairs & Provost
University of Miami
Director, Sylvester Comprehensive Cancer Center
Executive Dean for Research, Miller School of Medicine
Professor of Chemical, Environmental & Materials Engineering
Before joining the Miller School of Medicine in 2012, Dr. Nimer held several positions at Memorial Sloan-Kettering Cancer Center for almost 20 years. There, he served as the Alfred P. Sloan Chair in Cancer Research, head of the division of hematologic oncology, vice chairman for faculty development and chief of the Hematology Service. Under Dr. Nimer's leadership, Sylvester Comprehensive Cancer Center, which serves more than six million people in its catchment area and sits at the “gateway” to the Caribbean and Latin America, became an NCI-designated center in July 2019. It is the only NCI-designated cancer center in South Florida and the second youngest among all NCI-designated cancer centers. In 2022, U.S. News & World Report recognized Sylvester as a top-ranked cancer hospital in the nation. As a member of the University of Miami and the American Society of Hematology task forces that aim to address health disparities in different cultures, Dr. Nimer underscores the value of Sylvester, which offers a vastly multiethnic patient base — a veritable microcosm of what U.S. demographics are projected to be in 50+ years.
Dr. Nimer leads Sylvester’s research and experience with diverse community partnerships to create model approaches that address challenges and generate opportunities—all to prepare the cancer center for the future. Dr. Nimer shares this unique perspective through his service on external advisory boards for several NCI-designated cancer centers. Through key engagements and on-site advocacy, Dr. Nimer ensures cancer research remains at the forefront of efforts at the state and federal levels in contributing to meaningful cancer-related policies, innovative community care models and funding priorities. Since 2018 he has been a member of the Association of American Cancer Institutes, Nominating Committee and in 2020, he became a member of the Science Policy and Government Affairs Committee (SPGAC) of the American Association for Cancer Research.
Throughout his career, Dr. Nimer has cared for patients with myelodysplastic syndromes (MDS), acute myelogenous leukemia (AML), multiple myeloma and lymphoma and has decades of service to non-profits in their efforts to advance patient science and clinical care. He has chaired foundations including the MDS Foundation, the Leukemia & Lymphoma Society and the AAMDSIF. Moreover, he is the chairman of the Gabrielle’s Angel Foundation and Myelodysplastic Syndromes Foundation (MDSF), two organizations that award funding for early and senior career investigators, where Dr. Nimer performs oversight including grant reviews and convening board meetings.
Outside of his committee and foundation duties, Dr. Nimer has been continuously funded by the NIH for three decades and has served as PI on Leukemia and Lymphoma Society multi-project Specialized Center of Research awards. In his lab, Dr. Nimer focuses on understanding the genes involved in the development and progression of MDS and AML to identify novel therapeutic approaches to make hematologic cancers more responsive to treatment. Dr. Nimer holds two patents for the treatment of leukemia.
A physician-scientist in the field of hematology-oncology and cancer research, Dr. Nimer has authored more than 300 scientific publications and holds numerous awards including the Oscar de La Renta Endowed Chair in Cancer Research, the Irma T. Hirschl Career Scientist Award and he received the E. Donnall Thomas Award in 2015 from the Bone Marrow Foundation. In April 2021, the Academy of Science, Engineering and Medicine of Florida inducted Dr. Nimer to recognize his outstanding contributions to the scientific community. Similarly, the American Society of Clinical Investigators and the Association of American Physicians elected him to highlight his influential role in shaping the field of oncology. Dr. Nimer is also a Fellow of the American College of Physicians, further demonstrating his dedication to patient care and clinical excellence.
Vice Provost for Research and Scholarship
Professor of Medicine, Infectious Diseases
University of Miami
Start
End
Time
Item
Location
Proposed Speaker
Notes
Session Objective
8:45AM
9:30AM
0:45
Registration & Networking Breakfast
9:30AM
9:45AM
0:15
Welcome & Opening Remarks
~Maria Luisa Alcaide, M.D. Vice Provost for Research +Scholarship Professor of Medicine (Infectious Diseases) ~Stephen D. Nimer, M.D. Executive for Research, Miller School of Medicine
Overview/ Intros/ General Info/Housekeeping items
9:45AM
10:45AM
1:00
Strengthening Best Practices: Regulatory Requirements for Clinical Investigators
Emily Baldwin, Certified Investigator, Specialist, Office of Bioresearch Monitoring Inspectorate (OBMI), Office of Inspections and Investigations (OII), Food and Drug Administration (FDA)
~Identify applicable regulations for Clinical/Principal Investigators conducting FDA-regulated studies.
~Pinpoint additional best practices and procedures to protect subjects and enhance the reliability of collected data.
~Distinguish trends found on Form FDA 483s for Clinical/Principal Investigator inspections in fiscal year 2023.
10:45AM
11:45AM
1:00
Biostatistics in Clinical Trials
~Dr. Shiowjen Lee, PhD Deputy Division Director, Office of Biostatistics & Pharmacovigilance, Center for Biologics & Evaluation and Research (CBER), Food & Drug Administration (FDA); ~Dr. Shari Messenger, PhD Director of Biostatistics Collaboration & Consulting Core (University of Miami)
Understand the role of statisticians in clinical trials; Discuss expectations for successful collaboration; Highlight available resources
11:45AM
12:00PM
0:15
Morning Break
12:00PM
1:00PM
1:00
Hot Topics in Clinical Research Compliance
~Sujatha Sridhar, MBBS, MCE Associate Vice President, Research Compliance, University of Texas Health Science Center at Houston ~Jennifer McCafferty-Fernandez; Managing Partner, Critical Path Advisors, LLC ~Kenneth Goodman, PhD, FACMI, FACE Director, Institute for Bioethics & Health Policy; DIrector, UM Ethics Program
Strategies to enhance patient engagement, reduce burden, and incorporate patient-reported outcomes, including the ethical considerations of involving patients as research partners. The increasing use of real-world data from electronic health records, wearables, and other sources to complement traditional clinical trial data, and its implications for regulatory decisions and personalized medicine. How AI is transforming trial design, patient recruitment, data analysis, and predictive modeling, and what ethical and practical challenges arise with its integration. o Addressing the ongoing push to include underrepresented populations in research, the barriers to achieving this goal, and the impact on generalizability of trial results. o How genetic profiling, molecular diagnostics, and targeted therapies are reshaping clinical research, with a focus on challenges in implementation and equitable access.
1:00PM
1:45 PM
0:45
Networking Lunch
1:45PM
2:45PM
1:00
Clinical Trials at the U
~Dr. Leigh Nattkemper, PhD
Assistant Professor
Director of Clinical Trials
Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery
Miami Itch Center
University of Miami
~Laura Kozma
Associate Vice President
Office of Research Administration
University of Miami
~Nicole McCullough, MS, CCRP
Investigator Initiated Trial Services at the U (IITS-U)
Office of the Executive Dean for Research
University of Miami Miller School of Medicine
~Philip Arlen, PhD
Executive Director
Clinical Research Services
Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine
~Understand institutional requirements for start-up of a clinical trial ~Showcase some center and department examples of clinical trial processes ~Highlight some common obstacles with start-up and conduct of clinical trials at the U and how they are addressed
2:45PM
3:00PM
0:15
Afternoon Break
3:00PM
4:00PM
1:00
FDA - Clinical trials policy, evolving issues/ initiatives, vulnerable populations (virtual)
Dr. Shari Targum, MD, PhD Deputy Director, Office of Clinical Policy
Office of the Chief Medical Officer
US Food & Drug Administration
~Discuss clinical trials involving vulnerable populations and the associated regulatory challenges & expectations;
~Explore policies and regulatory guidance in clinical trials;
~Discuss modernization of clinical trials
4:00PM
4:30PM
0:30
Closing Remarks/ Announcements
Guillermo (Willy) Prado, PhD Interim Executive Vice President for Acadmic Affairs & Provost